Accendra Health Inc key statistics and ratios
In fiscal 2025, Accendra Health Inc had an operating margin of 1.0% and a current ratio of 0.58. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 10.1% | 9.9% | 9.9% | 10.4% | 12.3% | 12.4% | 12.4% | 12.2% | 12.6% | 11.4% | 12.3% | 15.1% | 15.5% | 18.3% | 83.3% | 82.8% | 46.7% | 44.8% |
| Operating margin | 2.5% | 2.4% | 2.4% | 2.2% | 2.2% | 1.7% | 2.1% | 2.1% | 1.0% | −3.7% | 0.8% | 2.4% | 3.8% | 1.4% | 5.2% | −8.1% | 1.0% | 1.1% |
| Net margin | 1.3% | 1.4% | 1.3% | 1.2% | 1.2% | 0.7% | 1.1% | 1.1% | 0.8% | −4.6% | −0.7% | 0.4% | 2.3% | 0.2% | −1.6% | −13.5% | −39.8% | −11.4% |
| Free-cash-flow margin | 2.5% | 1.4% | 0.5% | 2.4% | 1.2% | −0.6% | 2.6% | 1.7% | 0.2% | 0.8% | 1.3% | 3.4% | 0.9% | 1.7% | 22.3% | −0.3% | −10.6% | −13.5% |
| Return on equity | 13.6% | 13.6% | 13.0% | 11.5% | 11.1% | 6.6% | 10.4% | 11.1% | 7.4% | −57.0% | −12.7% | 5.1% | 26.9% | 2.4% | −4.3% | −47.4% | — | — |
| Return on assets | 6.0% | 6.2% | 6.1% | 5.2% | 4.9% | 2.6% | 3.8% | 4.0% | 2.4% | −12.2% | −1.7% | 0.9% | 6.4% | 0.5% | −0.8% | −7.4% | −31.0% | −13.3% |
| Asset turnover | 4.60 | 4.55 | 4.58 | 4.26 | 4.00 | 3.73 | 3.55 | 3.54 | 3.06 | 2.63 | 2.48 | 2.43 | 2.85 | 2.23 | 0.49 | 0.55 | 0.78 | 1.16 |
| Current ratio | 1.92 | 2.02 | 2.08 | 1.76 | 1.74 | 1.93 | 1.86 | 1.90 | 1.67 | 1.72 | 1.70 | 1.59 | 1.73 | 1.47 | 1.11 | 1.09 | 0.58 | 0.41 |
| Debt to equity | 27.1% | 24.6% | 23.4% | 22.4% | 21.1% | 61.9% | 57.8% | 59.3% | 90.3% | 323.4% | 337.5% | 144.1% | 101.0% | 258.7% | 221.9% | 314.0% | — | — |
| Interest cover (operating income ÷ interest) | 15.4x | 13.7x | 14.9x | 14.7x | 15.1x | 8.8x | 7.4x | 7.4x | 2.8x | n/m | 0.7x | 2.4x | 7.7x | 1.1x | 1.1x | n/m | 0.3x | 0.2x |
| Effective tax rate | 37.9% | 39.1% | 39.3% | 40.6% | 40.1% | 47.4% | 40.3% | 37.0% | −26.6% | — | — | 19.9% | 19.9% | — | 41.7% | — | — | — |
| R&D as % of revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0.1% | 0.1% | 0.5% | 0.5% | — | — |
| SG&A as % of revenue | 7.4% | 6.9% | 7.1% | 7.7% | 9.5% | 10.4% | 10.2% | 10.0% | 10.9% | 10.1% | 11.1% | 12.3% | 11.0% | 15.6% | 39.2% | 40.4% | 38.7% | 39.1% |
| Capital spending as % of revenue | 0.2% | 0.4% | 0.3% | 0.1% | 0.3% | 0.5% | 0.2% | 0.2% | 0.4% | 0.5% | 0.5% | 0.6% | 0.4% | 1.6% | 6.8% | 6.4% | 6.9% | 6.7% |
| Free cash flow ÷ net income | 189.5% | 101.3% | 37.7% | 191.4% | 101.4% | −78.5% | 241.5% | 153.9% | 30.4% | — | — | 966.8% | 37.5% | 745.5% | — | — | — | — |
| Dividends ÷ net income | 36.7% | 40.5% | 44.2% | 51.1% | 54.8% | 94.9% | 61.6% | 58.3% | 86.8% | — | — | 2.2% | 0.3% | 0.0% | — | — | — | — |
| Dividends and buybacks ÷ free cash flow | 19.4% | 40.0% | 154.3% | 33.9% | 70.8% | — | 33.5% | 80.3% | 307.5% | 68.2% | 4.2% | 0.2% | 0.9% | 0.0% | 0.0% | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 81.5% | 83.4% | 78.1% | 47.6% | 46.2% | 45.6% | 44.3% | 43.0% |
| Operating margin | 4.5% | −39.2% | 2.9% | −5.8% | 3.8% | 2.9% | 2.7% | −5.7% |
| Net margin | −1.9% | −42.6% | −3.7% | −127.4% | −21.6% | −7.9% | −1.0% | −14.5% |
| Free-cash-flow margin | −5.0% | 7.0% | −12.0% | −2.9% | −35.4% | 7.8% | −14.6% | −12.0% |
| Current ratio | 1.09 | 1.09 | 1.13 | 0.86 | 0.86 | 0.58 | 0.49 | 0.41 |
| Debt to equity | 210.4% | 314.0% | 341.1% | — | — | — | — | — |
| SG&A as % of revenue | 39.6% | 38.8% | 38.9% | 39.3% | 38.1% | 38.3% | 40.7% | 39.7% |
Financial health
- Short-term assets cover short-term liabilities $271m of assets due within a year against $666m of liabilities due within a year.
- Short-term assets cover long-term liabilities $271m short-term assets against $2.0bn of longer-dated liabilities.
- More cash than debt $8m of cash against $1.7bn of debt.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$180m of operating cash flow against $1.7bn of debt.
- Operating profit covers interest at least five times over Operating income of $29m against $124m of interest.
Moat
Weak moat
How hard Accendra Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -2.6% of total assets over 10 years.
- Pricing power 0 / 20
Gross margin has been a median 15.7%, moving by 22.3 percentage points (standard deviation) across 10 years.
- Durability 0 / 20
Operating margin has been a median 1.0%; its worst year was -9.6%.
- Cash conversion 9 / 20
Free cash flow was positive in 8 of 10 years, at a median 1.3% of revenue.
- Discipline 13 / 20
The diluted share count rose 9.8% over five years; stock-based pay has been a median 0.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (22 before it).
Compare with peers
- 111, Inc. statistics
- Henry Schein statistics
- Cosmos Health Inc. statistics
- Cencora statistics
- McKesson statistics
Head to head: ACH vs YIACH vs HSICACH vs COSM
More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies